NASDAQ:TNDM - Tandem Diabetes Care Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $123.11
  • Forecasted Upside: 20.64 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.3 (-0.29%)

This chart shows the closing price for TNDM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tandem Diabetes Care Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNDM

Analyst Price Target is $123.11
▲ +20.64% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $123.11, with a high forecast of $150.00 and a low forecast of $90.00. The average price target represents a 20.64% upside from the last price of $102.05.

This chart shows the closing price for TNDM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Tandem Diabetes Care. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021BarclaysInitiated CoverageUnderweight$90.00Low
5/6/2021OppenheimerBoost Price Target$130.00 ➝ $135.00Low
5/6/2021SVB LeerinkBoost Price TargetMarket Perform$95.00 ➝ $102.00High
4/1/2021SVB LeerinkLower Price TargetMarket Perform$115.00 ➝ $95.00Low
3/31/2021OppenheimerReiterated RatingBuyHigh
2/25/2021Lake Street CapitalBoost Price TargetBuy$137.00 ➝ $150.00High
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$105.00High
11/6/2020Raymond JamesBoost Price TargetOutperform$116.00 ➝ $124.00High
11/6/2020SVB LeerinkBoost Price TargetMarket Perform$120.00 ➝ $130.00High
11/6/2020Piper SandlerBoost Price TargetOverweight$125.00 ➝ $132.00High
9/21/2020OppenheimerReiterated RatingBuy$120.00High
8/28/2020SVB LeerinkBoost Price TargetMarket Perform$115.00 ➝ $120.00Low
8/20/2020Wells Fargo & CompanyInitiated CoverageOverweight$120.00High
7/31/2020Raymond JamesBoost Price TargetOutperform$95.00 ➝ $116.00Low
7/31/2020Craig HallumBoost Price TargetBuy$102.00 ➝ $140.00High
7/31/2020Lake Street CapitalBoost Price TargetPositive ➝ Buy$125.00 ➝ $137.00High
7/31/2020SVB LeerinkBoost Price TargetMarket Perform$105.00 ➝ $115.00High
7/31/2020GuggenheimUpgradeNeutral ➝ Buy$130.00High
7/31/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $125.00High
7/7/2020CowenBoost Price TargetPositive ➝ Outperform$85.00 ➝ $110.00Low
7/6/2020CitigroupUpgradeNeutral ➝ Buy$94.00 ➝ $120.00Low
6/30/2020OppenheimerInitiated CoverageBuy$102.00Low
6/30/2020Piper SandlerReiterated RatingBuy$90.00Low
6/30/2020Bank of AmericaReiterated RatingHold$100.00Low
6/30/2020CowenReiterated RatingBuy$85.00Low
6/22/2020UBS GroupBoost Price TargetBuy$98.00 ➝ $106.00Low
6/22/2020OppenheimerBoost Price TargetReduce ➝ Outperform$92.00 ➝ $102.00Low
6/18/2020Lake Street CapitalBoost Price Target$100.00 ➝ $125.00Low
6/18/2020Raymond JamesBoost Price TargetOutperform$88.00 ➝ $95.00Low
6/17/2020OppenheimerInitiated CoverageBuy$92.00Low
6/3/2020CitigroupBoost Price TargetAverage ➝ Neutral$81.00 ➝ $94.00Low
5/22/2020Bank of AmericaBoost Price TargetNeutral$85.00 ➝ $95.00Low
5/1/2020UBS GroupLower Price TargetBuy$100.00 ➝ $98.00High
5/1/2020CitigroupBoost Price TargetNeutral$74.00 ➝ $81.00High
5/1/2020Stifel NicolausBoost Price TargetHold$65.00 ➝ $75.00Medium
5/1/2020OppenheimerReiterated RatingBuy$92.00High
5/1/2020SVB LeerinkBoost Price TargetMarket Perform$85.00 ➝ $88.00High
4/27/2020Raymond JamesLower Price TargetOutperform$91.00 ➝ $81.00Low
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
4/20/2020Craig HallumLower Price TargetBuy$108.00 ➝ $102.00Medium
3/27/2020CitigroupLower Price TargetNeutral$89.00 ➝ $74.00High
3/23/2020GuggenheimDowngradeBuy ➝ NeutralHigh
3/4/2020CitigroupInitiated CoverageNeutral$89.00Medium
2/25/2020OppenheimerBoost Price Target$84.00 ➝ $97.00High
2/25/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $90.00High
2/25/2020Craig HallumBoost Price TargetBuy$92.00 ➝ $108.00High
2/25/2020Stifel NicolausBoost Price TargetHold$70.00 ➝ $77.00High
2/25/2020Raymond JamesBoost Price TargetOutperform$85.00 ➝ $91.00High
2/25/2020CowenReiterated RatingOutperform$85.00 ➝ $90.00High
2/13/2020CowenBoost Price TargetOutperform$70.00 ➝ $85.00Medium
2/12/2020Craig HallumReiterated RatingBuy$92.00High
2/5/2020Raymond JamesInitiated CoverageOutperform$85.00Low
2/4/2020Robert W. BairdDowngradeOutperform ➝ Neutral$71.00 ➝ $75.00Low
12/13/2019Craig HallumReiterated RatingBuy$92.00Low
10/17/2019GuggenheimInitiated CoverageBuy$76.00Low
10/4/2019UBS GroupUpgradeNeutral ➝ Buy$75.00Low
8/2/2019OppenheimerBoost Price Target$80.00 ➝ $84.00Medium
6/17/2019Lake Street CapitalReiterated RatingBuyMedium
5/17/2019Bank of AmericaReiterated RatingNeutral$65.00Medium
5/13/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$83.00Low
5/1/2019OppenheimerBoost Price TargetOutperform$68.00 ➝ $80.00Medium
5/1/2019Stifel NicolausBoost Price TargetHold ➝ Hold$58.00 ➝ $70.00Medium
5/1/2019Craig HallumReiterated RatingBuy$70.00 ➝ $84.00High
4/30/2019UBS GroupBoost Price TargetNeutral ➝ Neutral$53.00 ➝ $66.00High
3/8/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$77.00High
3/5/2019Bank of AmericaBoost Price TargetNeutral$59.00 ➝ $65.00Low
2/27/2019OppenheimerBoost Price TargetOutperform$57.00 ➝ $68.00Medium
2/27/2019CowenBoost Price TargetOutperform$40.00 ➝ $60.00Medium
2/27/2019Craig HallumBoost Price TargetBuy$59.00 ➝ $70.00Medium
2/27/2019Lake Street CapitalBoost Price TargetBuy ➝ Buy$60.00 ➝ $100.00High
2/27/2019Piper Jaffray CompaniesUpgradeOverweight$67.00High
2/15/2019Robert W. BairdBoost Price TargetOutperform$46.00 ➝ $55.00Medium
11/27/2018UBS GroupInitiated CoverageNeutral$36.00High
11/21/2018Robert W. BairdUpgradeNeutral ➝ Outperform$46.00High
11/9/2018OppenheimerSet Price TargetBuy$57.00Medium
11/3/2018Lake Street CapitalSet Price TargetBuy$60.00High
11/2/2018Craig HallumSet Price TargetBuy$59.00High
11/2/2018OppenheimerSet Price TargetBuy$57.00High
10/15/2018Lake Street CapitalSet Price TargetBuy$60.00High
9/26/2018Dougherty & CoBoost Price TargetBuy$45.00 ➝ $56.00Low
9/26/2018Piper Jaffray CompaniesReiterated RatingAbove Average ➝ Overweight$32.00 ➝ $56.00Medium
9/25/2018OppenheimerReiterated RatingBuy$57.00Low
9/20/2018Craig HallumInitiated CoverageBuy$52.00 ➝ $52.00Low
9/14/2018Robert W. BairdDowngradeOutperform ➝ NeutralMedium
9/5/2018OppenheimerSet Price TargetBuy$54.00High
8/30/2018Berenberg BankInitiated CoverageBuy ➝ Buy$50.00High
8/24/2018Dougherty & CoInitiated CoverageBuy ➝ Buy$45.00High
8/24/2018Bank of AmericaUpgradeUnderperform ➝ Neutral$45.00High
8/22/2018Stifel NicolausInitiated CoverageHold$25.00 ➝ $34.00High
8/20/2018Lake Street CapitalBoost Price TargetBuy$35.00 ➝ $65.00Low
8/6/2018OppenheimerSet Price TargetBuy$31.00 ➝ $38.00High
7/31/2018OppenheimerSet Price TargetBuy$31.00High
7/31/2018Lake Street CapitalBoost Price TargetBuy$35.00High
7/31/2018Piper Jaffray CompaniesBoost Price TargetOverweight$32.00High
7/31/2018Stifel NicolausReiterated RatingHold ➝ Hold$7.50 ➝ $25.00High
7/31/2018CowenReiterated RatingBuy$28.00High
7/23/2018Robert W. BairdReiterated RatingBuy$31.00High
6/22/2018Piper Jaffray CompaniesUpgradeOverweight$25.00High
6/18/2018Lake Street CapitalInitiated CoverageBuy$30.00High
5/27/2018OppenheimerSet Price TargetBuy$15.00High
5/21/2018OppenheimerSet Price TargetBuy$10.00 ➝ $15.00High
5/14/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightHigh
4/6/2018OppenheimerSet Price TargetBuy$8.00High
3/28/2018CowenUpgradeMarket Perform ➝ OutperformMedium
3/23/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
3/22/2018OppenheimerReiterated RatingBuyMedium
3/2/2018Stifel NicolausReiterated RatingHold$4.00High
2/27/2018CowenReiterated RatingHoldMedium
2/27/2018CitigroupInitiated CoverageOutperform$5.50Low
2/26/2018OppenheimerInitiated CoverageBuy$5.50 ➝ $6.00High
11/19/2017Robert W. BairdReiterated RatingHold$3.00N/A
10/10/2017WedbushReiterated RatingOutperform$50.00 ➝ $17.00N/A
10/6/2017Piper Jaffray CompaniesReiterated RatingHold$15.00N/A
5/3/2017B. RileyReiterated RatingNeutral$15.00Medium
4/28/2017B. RileyReiterated RatingNeutral$15.00Low
4/10/2017CowenDowngradeOutperform ➝ Market Perform$15.00Medium
3/30/2017WedbushReiterated RatingOutperform$110.00Low
3/30/2017Piper Jaffray CompaniesReiterated RatingNeutral ➝ NeutralMedium
3/29/2017B. RileyDowngradeNeutral$15.00Medium
3/24/2017B. RileyDowngradeBuy ➝ Neutral$50.00 ➝ $15.00Low
3/11/2017B. RileyReiterated RatingBuy$50.00N/A
3/9/2017Northcoast ResearchReiterated RatingBuyN/A
1/24/2017WedbushReiterated RatingPositiveN/A
11/7/2016B. RileyReiterated RatingBuy$70.00N/A
11/3/2016Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/A
11/2/2016B. RileyReiterated RatingBuy$70.00N/A
11/2/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$140.00 ➝ $90.00N/A
11/2/2016Feltl & Co.DowngradeStrong-Buy ➝ BuyN/A
11/2/2016WedbushLower Price TargetOutperform$200.00 ➝ $110.00N/A
11/2/2016Robert W. BairdDowngradeOutperform ➝ Neutral$110.00 ➝ $40.00N/A
11/2/2016Stifel NicolausDowngradeBuy ➝ Hold$150.00 ➝ $35.00N/A
10/2/2016B. RileyInitiated CoverageBuy$100.00N/A
9/26/2016B. RileyInitiated CoverageBuy$100.00N/A
7/29/2016WedbushReiterated RatingOutperform$200.00N/A
(Data available from 7/28/2016 forward)
Tandem Diabetes Care logo
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $102.05
Low: $100.82
High: $103.21

50 Day Range

MA: $93.49
Low: $81.77
High: $104.02

52 Week Range

Now: $102.05
Low: $76.19
High: $123.74


392,266 shs

Average Volume

671,555 shs

Market Capitalization

$6.39 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Barclays PLC, Craig Hallum, Guggenheim, Lake Street Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for TNDM.

What is the current price target for Tandem Diabetes Care?

9 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $123.11, suggesting a possible upside of 20.6%. Lake Street Capital has the highest price target set, predicting TNDM will reach $150.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $90.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.

What is the current consensus analyst rating for Tandem Diabetes Care?

Tandem Diabetes Care currently has 1 sell rating, 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNDM will outperform the market and that investors should add to their positions of Tandem Diabetes Care.
View the latest ratings for TNDM.

What other companies compete with Tandem Diabetes Care?

How do I contact Tandem Diabetes Care's investor relations team?

Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is (858) 366-6900 and its investor relations email address is [email protected] The official website for Tandem Diabetes Care is